Demographic and Clinical Characteristics | N | % | |
---|---|---|---|
GEP-NENs (n = 286) | |||
Sex | Male | 173 | 60.5 |
Female | 113 | 39.5 | |
Age (years) at diagnosis | ≤50 | 134 | 46.9 |
> 50 | 152 | 53.1 | |
Median (range) | 53 (16–85) | ||
Functional status | Nonfunctional | 234 | 81.8 |
Functional | 52 | 18.2 | |
Insulinoma | 42 | 14.7 | |
Vasoactive intestinal polypeptidoma | 7 | 2.4 | |
Carcinoid syndrome | 1 | 0.3 | |
Somatostatinoma | 1 | 0.3 | |
Gastrinoma | 1 | 0.3 | |
Tumor location | Gastrointestinal tract | 162 | 56.6 |
Rectum | 60 | 21.0 | |
Stomach | 43 | 15.0 | |
Duodenum | 21 | 7.3 | |
Esophagus | 18 | 6.3 | |
Jejunum/ileum | 9 | 3.1 | |
Appendix | 6 | 2.1 | |
Colon | 5 | 1.7 | |
Pancreas | 93 | 32.5 | |
Other | 31 | 10.8 | |
Metastasis of unknown primary | 25 | 8.7 | |
Biliary tract | 5 | 1.7 | |
Greater omentum | 1 | 0.3 | |
Tumor gradea | G1 | 120 | 43.2 |
G2 | 57 | 20.5 | |
G3 | 101 | 36.3 | |
Tumor typea | NET | 180 | 64.7 |
NET G1 | 120 | 43.2 | |
NET G2 | 57 | 20.5 | |
NET G3 | 3 | 1.1 | |
NEC | 91 | 32.7 | |
MANEC | 7 | 2.5 | |
Tumor stage | I | 79 | 27.6 |
II | 61 | 21.3 | |
III | 45 | 15.7 | |
IV | 101 | 35.3 | |
GI-NENs (n = 162) | |||
Tumor gradeb | G1 | 60 | 38.5 |
G2 | 21 | 13.5 | |
G3 | 75 | 48.1 | |
Tumor typeb | NET | 81 | 51.9 |
NET G1 | 60 | 38.5 | |
NET G2 | 21 | 13.5 | |
NEC | 70 | 44.9 | |
MANEC | 5 | 3.2 | |
Tumor stage | I | 48 | 29.6 |
II | 26 | 16.0 | |
III | 37 | 22.8 | |
IV | 51 | 31.5 | |
pNENs (n = 93) | |||
Tumor gradec | G1 | 54 | 59.3 |
G2 | 27 | 29.7 | |
G3 | 10 | 11.0 | |
Tumor typec | NET | 84 | 92.3 |
NET G1 | 54 | 59.3 | |
NET G2 | 27 | 29.7 | |
NET G3 | 3 | 3.3 | |
NEC | 7 | 7.7 | |
MANEC | 0 | 0 | |
Tumor stage | I | 30 | 32.3 |
II | 30 | 32.3 | |
III | 4 | 4.3 | |
IV | 29 | 31.2 |